Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem resistant Acinetobacter baumannii bloodstream infections: cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality

References

• Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65(2):233–238.
   Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DE, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–762.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–2329.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309–317.
   PubMed Web of Science ®Google Scholar
• Magret M, Lisboa T, Martin-Loeches I, et al. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care. 2011;15(1):R62.
   PubMed Web of Science ®Google Scholar
• Nutman A, Glick R, Temkin E, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect. 2014;20(12):O1028–O1034.
   PubMed Web of Science ®Google Scholar
• Chopra T, Marchaim D, Awali RA, et al. Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother. 2013;57(12):6270–6275.
   PubMed Web of Science ®Google Scholar
• Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46(8):1254–1263.
   PubMed Web of Science ®Google Scholar
• Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist. 2010;16(3):209–215.
   PubMed Web of Science ®Google Scholar
• Xiao YH, Wang J, Zhao CY, et al. Mohnarin bacterial resistance surveillance 2006-2007. Chin J Nosocomiol. 2008;18:1051–1056.
   Google Scholar
• Hu FP, Zhu DM, Wang F, Jiang XF, Yc X, Zhang XJ. Chinet 2014 surveillance of bacterial resistance in China. Chin J Infect Chemother. 2015;15:401–410.
   Google Scholar
• Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care. 2006;10(2):R48.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Daily cost of delay to adequate antibiotic treatment among patients surviving a hospitalization with community-onset Acinetobacter baumannii pneumonia or sepsis. Crit Care. 2017;21(1):130.
   PubMedGoogle Scholar
• Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51(1):79–84.
   PubMed Web of Science ®Google Scholar
• Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74(12):1315–1333.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. In: CLSI Document M100-S25. Wayne, PA; 2015.
   Google Scholar
• Liu X, Zheng H, Zhang W, et al. Tracking cefoperazone/sulbactam resistance development in vivo in A. baumannii isolated from a patient with hospital-acquired pneumonia by whole-genome sequencing. Front Microbiol. 2016;7:1268.
   PubMed Web of Science ®Google Scholar
• TYGACIL (tigecycline) [Package Insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2005.
   Google Scholar
• García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis. 2001;33(7):939–946.
   PubMed Web of Science ®Google Scholar
• Ye JJ, Huang CT, Shie SS, et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One. 2010;5(4):e9947.
   PubMedGoogle Scholar
• Chusri S, Silpapojakul K, Mcneil E, Singkhamanan K, Chongsuvivatwong V. Impact of antibiotic exposure on occurrence of nosocomial carbapenem-resistant Acinetobacter baumannii infection: a case control study. J Infect Chemother. 2015;21(2):90–95.
   PubMed Web of Science ®Google Scholar
• Choi JY, Kim CO, Park YS, et al. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia. Yonsei Med J. 2006;47(1):63–69.
   PubMed Web of Science ®Google Scholar
• Gao C, Tong J, Yu K, Sun Z, An R, du Z. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration. Eur J Clin Pharmacol. 2016;72(7):823–830.
   PubMed Web of Science ®Google Scholar
• Hu FP, Guo Y, Zhu DM, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9–14.
   PubMed Web of Science ®Google Scholar
• Ogutlu A, Guclu E, Karabay O, Utku AC, Tuna N, Yahyaoglu M. Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob. 2014;13:7.
   PubMed Web of Science ®Google Scholar
• Erbay A, Idil A, Gözel MG, Mumcuoğlu I, Balaban N. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agents. 2009;34(6):575–579.
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. 2007;27(7):980–987.
   PubMed Web of Science ®Google Scholar
• Curcio D. Off-label use of antibiotics in hospitalized patients: focus on tigecycline. J Antimicrob Chemother. 2009;64(6):1344–1346.
   PubMed Web of Science ®Google Scholar
• Curcio D, Fernández F, Cané A, Barcelona L, Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis. 2008;12(3):198–201.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA drug safety communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections; 2010 [September 1]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed April 18, 2011.
   Google Scholar
• Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844.
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54(12):1699–1709.
   PubMed Web of Science ®Google Scholar
• Chinese XDR Consensus Working Group, Guan X, He L, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22(Suppl 1):S15–S25.
   PubMed Web of Science ®Google Scholar
• Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41(suppl 5):S333–S340.
   PubMed Web of Science ®Google Scholar